Phase 1/2a Study of the Malaria Vaccine Candidate Apical Membrane Antigen-1 (AMA-1) Administered in Adjuvant System AS01B or AS02A

Collection UNKNOWN
D. Spring, Michele; F. Cummings, James; F. Ockenhouse, Christian; Dutta, Sheetij; Reidler, Randall; Angov, Evelina; Bergmann-Leitner, Elke; Ann Stewart, V.; Bittner, Stacey; Juompan, Laure; G. Kortepeter, Mark; Nielsen, Robin; Krzych, Urszula; Tierney, Ev; A. Ware, Lisa; Dowler, Megan; C. Hermsen, Cornelus; W. Sauerwein, Robert; J. de Vlas, Sake; Ofori-Anyinam, Opokua; E. Lanar, David; L. Williams, Jack; E. Kester, Kent; Tucker, Kathryn; Shi, Meng; Malkin, Elissa; Long, Carole; L. Diggs, Carter; Soisson, Lorraine; Dubois, Marie-Claude; ... view all 33 authors
  • Publisher: Figshare
  • Related identifiers: doi: 10.1371/journal.pone.0005254
  • Subject: membrane | as01b | apical | adjuvant | as02a | Microbiology | antigen-1 | Cancer | malaria | administered | Immunology
    mesheuropmc: parasitic diseases

<div><h3>Background</h3><p>This Phase 1/2a study evaluated the safety, immunogenicity, and efficacy of an experimental malaria vaccine comprised of the recombinant <em>Plasmodium falciparum</em> protein apical membrane antigen-1 (AMA-1) representing the 3D7 allele formu... View more
Share - Bookmark

  • Download from
    figshare via figshare (Collection)
  • Cite this research product